Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | UBE2M | P61081 | 1/20 | 0.49 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.43 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1470584 | 0.91 | KMT2A (0.52) | KMT2AL3MBTL1MCHR1DRD2DRD4 | |
| SCHEMBL1470579 | 0.91 | KMT2A (0.52) | KMT2AL3MBTL1MCHR1DRD2DRD4 | |
| SCHEMBL1470577 | 0.91 | KMT2A (0.52) | KMT2AL3MBTL1MCHR1DRD2DRD4 | |
| SCHEMBL8741001 | 0.90 | KMT2A (0.52) | KMT2AL3MBTL1DRD2DRD4DRD3 | |
| SCHEMBL7825129 | 0.90 | KMT2A (0.52) | KMT2AL3MBTL1DRD2DRD4DRD3 | |
| SCHEMBL7825124 | 0.90 | KMT2A (0.52) | KMT2AL3MBTL1DRD2DRD4DRD3 | |
| SCHEMBL7825126 | 0.90 | KMT2A (0.52) | KMT2AL3MBTL1DRD2DRD4DRD3 | |
| SCHEMBL4369305 | 0.88 | DRD2 (0.56) | KMT2AL3MBTL1MCHR1DRD2DRD4 | |
| SCHEMBL4369301 | 0.88 | DRD2 (0.56) | KMT2AL3MBTL1MCHR1DRD2DRD4 | |
| SCHEMBL4372426 | 0.88 | DRD2 (0.56) | KMT2AL3MBTL1MCHR1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138204-B2 | Emesis, dyspepsia, gastroparesis, constipation, gastroesophageal reflux, or post-operative ileus; cisapride analogs; side effect reduction of adverse events; (R)-quinuclidin-3-yl 6-((3S,4R)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)hexanoate or salts | ARYX THERAPEUTICS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-7629466-B2 | Synthetic methods and intermediates for steroisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090137810-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080085915-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085921-A1 | Stereoisomeric Compounds And Methods For The Treatment Of Gastrointestinal And Central Nervous System Disorders | ARYX THERAPEUTICS (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080076927-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7326787-B2 | Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7282509-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070078265-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS (US) | 2007-04-05 | — | — | US | disclosed |
| US-7176218-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085921-A1 | Stereoisomeric Compounds And Methods For The Treatment Of Gastrointestinal And Central Nervous System Disorders | CCKBR, GRPR, HRH2 | KMT2A 3667/4885L3MBTL1 4670/4885UBE2M 1176/4885 |
| US-20080076927-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | KMT2A 4193/4885L3MBTL1 4171/4885UBE2M 1755/4885 |
| US-20080085915-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | CCKBR, HRH2, GRPR | KMT2A 3215/4885L3MBTL1 4557/4885UBE2M 1208/4885 |
| US-20090137810-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | KMT2A 4193/4885L3MBTL1 4171/4885UBE2M 1755/4885 |
| US-20070078265-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | KMT2A 4193/4885L3MBTL1 4171/4885UBE2M 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.